Postmenopausal hormone therapy in prior pre-eclamptic women: a nationwide cohort study in Finland.

IF 2.9 4区医学 Q1 OBSTETRICS & GYNECOLOGY

Climacteric Pub Date : 2023-12-01 Epub Date: 2023-07-21 DOI:10.1080/13697137.2023.2228687

M Venetkoski, O Ylikorkala, J M Joensuu, M Gissler, T S Mikkola, H Savolainen-Peltonen

{"title":"Postmenopausal hormone therapy in prior pre-eclamptic women: a nationwide cohort study in Finland.","authors":"M Venetkoski, O Ylikorkala, J M Joensuu, M Gissler, T S Mikkola, H Savolainen-Peltonen","doi":"10.1080/13697137.2023.2228687","DOIUrl":null,"url":null,"abstract":"Objective: We compared the trends of hormone therapy (HT) use among women with and without a history of pre-eclampsia.Methods: This national cohort study consisted of women with a pre-eclamptic pregnancy (n = 31,688) or a normotensive pregnancy (n = 91,726) (controls) during 1969-1993. The data on their use of HT during 1994-2019 were traced from the National Medicine Reimbursement Register.Results: Both women with a history of pre-eclampsia and controls initiated HT at a mean age of 49.9 years. Cumulative HT™ use during the total follow-up did not differ between the groups (31.1% vs. 30.6%, p = 0.066). However, HT use in previously pre-eclamptic women was less common in 1994-2006 (20.2% vs. 22.4%, p < 0.001) and more common in 2007-2019 (22.1% vs. 21.1%, p < 0.001) than in controls. This trend was also seen in the annual changes of HT starters. Women with a history of pre-eclampsia used HT for a shorter time (6.3 vs. 7.1 years, p < 0.001).Conclusions: In contrast to controls, HT use in previously pre-eclamptic women increased during the last half of the follow-up. This may reflect the changes in the international recommendations, the increased awareness of pre-eclampsia-related cardiovascular risk later in life and the aim to diminish this risk with HT.","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"571-576"},"PeriodicalIF":2.9000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Climacteric","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13697137.2023.2228687","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/21 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: We compared the trends of hormone therapy (HT) use among women with and without a history of pre-eclampsia.

Methods: This national cohort study consisted of women with a pre-eclamptic pregnancy (n = 31,688) or a normotensive pregnancy (n = 91,726) (controls) during 1969-1993. The data on their use of HT during 1994-2019 were traced from the National Medicine Reimbursement Register.

Results: Both women with a history of pre-eclampsia and controls initiated HT at a mean age of 49.9 years. Cumulative HT™ use during the total follow-up did not differ between the groups (31.1% vs. 30.6%, p = 0.066). However, HT use in previously pre-eclamptic women was less common in 1994-2006 (20.2% vs. 22.4%, p < 0.001) and more common in 2007-2019 (22.1% vs. 21.1%, p < 0.001) than in controls. This trend was also seen in the annual changes of HT starters. Women with a history of pre-eclampsia used HT for a shorter time (6.3 vs. 7.1 years, p < 0.001).

Conclusions: In contrast to controls, HT use in previously pre-eclamptic women increased during the last half of the follow-up. This may reflect the changes in the international recommendations, the increased awareness of pre-eclampsia-related cardiovascular risk later in life and the aim to diminish this risk with HT.

查看原文本刊更多论文

绝经后激素治疗先前子痫前期妇女:芬兰全国队列研究。

目的:我们比较有和没有先兆子痫病史的妇女使用激素治疗(HT)的趋势。方法:这项国家队列研究包括1969-1993年间有子痫前期妊娠(n = 31688)或正常妊娠(n = 91726)的妇女(对照)。他们在1994-2019年期间使用HT的数据来自国家药品报销登记册。结果:两名有先兆子痫病史的女性和对照组开始HT的平均年龄为49.9岁。在总随访期间，两组之间的累计HT使用没有差异(31.1%对30.6%，p = 0.066)。然而，1994-2006年间，曾有子痫前期妇女使用激素的情况较少见(20.2%对22.4%，p p p)。结论:与对照组相比，曾有子痫前期妇女使用激素的情况在随访的后半段有所增加。这可能反映了国际建议的变化，对子痫前期相关心血管风险的认识的提高，以及通过HT降低这种风险的目的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Climacteric 医学-妇产科学

CiteScore

1.70

自引率

7.10%

发文量

审稿时长

1 months

期刊介绍： Climacteric is the official journal of the International Menopause Society (IMS). As an international peer-reviewed journal it publishes original research and reviews of all aspects of aging in women. Climacteric was founded by the IMS in 1998 and today has become a leading journal in the publication of peer-reviewed papers on the menopause, climacteric and mid-life health. Topics covered include endocrine changes, symptoms attributed to the menopause and their treatment, hormone replacement and alternative therapies, lifestyles, and the counselling and education of peri- and postmenopausal women. Climacteric, published bimonthly, also features regular invited reviews, editorials and commentaries on recent developments. The editorial review board of Climacteric includes leading scientific and clinical experts in the field of midlife medicine and research and is headed by its Editor-in-Chief, Professor Rod Baber of Australia. He and his team of Associate Editors act independently to set a clear editorial policy, co-ordinate peer review, and ensure a rapid response to submitted papers.